0001209191-21-047263.txt : 20210719
0001209191-21-047263.hdr.sgml : 20210719
20210719195213
ACCESSION NUMBER: 0001209191-21-047263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210715
FILED AS OF DATE: 20210719
DATE AS OF CHANGE: 20210719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Glenn Gregory M
CENTRAL INDEX KEY: 0001342823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 211099097
MAIL ADDRESS:
STREET 1: 20 FIRSTFIELD ROAD, #250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-15
0
0001000694
NOVAVAX INC
NVAX
0001342823
Glenn Gregory M
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
GAITHERSBURG
MD
20878
0
1
0
0
President, R&D
Common Stock
2021-07-15
4
M
0
550
27.00
A
3361
D
Common Stock
2021-07-15
4
M
0
870
27.60
A
4231
D
Common Stock
2021-07-15
4
M
0
1105
46.00
A
5336
D
Common Stock
2021-07-15
4
M
0
3129
5.95
A
8465
D
Common Stock
2021-07-15
4
S
0
730
177.6225
D
7735
D
Common Stock
2021-07-15
4
S
0
2318
178.1931
D
5417
D
Common Stock
2021-07-15
4
S
0
796
179.2935
D
4621
D
Common Stock
2021-07-15
4
S
0
550
180.5727
D
4071
D
Common Stock
2021-07-15
4
S
0
560
181.4469
D
3511
D
Common Stock
2021-07-15
4
S
0
300
182.3766
D
3211
D
Common Stock
2021-07-15
4
S
0
399
183.8114
D
2812
D
Common Stock
2021-07-15
4
S
0
1
184.2704
D
2811
D
Common Stock
2021-07-15
4
M
0
4823
5.95
A
7634
D
Common Stock
2021-07-15
4
D
0
161
179.14
D
7473
D
Common Stock
2021-07-15
4
F
0
2253
179.14
D
5220
D
Stock Option (Right to Buy)
27.00
2021-07-15
4
M
0
550
0.00
D
2026-11-14
Common Stock
550
0
D
Stock Option (Right to Buy)
27.60
2021-07-15
4
M
0
870
0.00
D
2027-12-15
Common Stock
870
3131
D
Stock Option (Right to Buy)
46.00
2021-07-15
4
M
0
1105
0.00
D
2028-12-13
Common Stock
1105
11914
D
Stock Option (Right to Buy)
5.95
2021-07-15
4
M
0
3129
0.00
D
2029-09-26
Common Stock
3129
56251
D
Stock Appreciation Right
5.95
2021-07-15
4
M
0
4823
0.00
D
2029-09-26
Common Stock
4823
37182
D
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.9859 to $177.96, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.988 to $178.9871, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.0099 to $179.9087, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.14 to $180.9008, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.1643 to $182.0783, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.19 to $182.5638, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.1998 to $184.1349, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reporting person received 2,409 shares of common stock upon the net exercise of 4,823 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 161 shares of common stock underlying the stock appreciation rights representing the base value and 2,253 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on July 15, 2021 of $179.14.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the November 14, 2016 grant date and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
/s/ John A. Herrmann III, Attorney-in-Fact
2021-07-19